FDA Approves ZYN Nicotine Pouches

Nicotine pouches get FDA approval, with some calling them Gen Z's favorite weight loss hack
Little pouches of nicotine sold by the brand ZYN were given the green light for marketing this week through the U.S. Food and Drug Administration’s premarket tobacco product application (PMTA) pathway.
Zyn nicotine pouches, dubbed 'Gen Z’s weight loss secret,' secure FDA approval
Zyn gains cult status among Gen Z, praised for boosting workouts, alertness, and dubbed O-Zyn-pic for weight loss.
FDA Approves Marketing of Nicotine Pouches
Following an extensive scientific review, the U.S. Food and Drug Administration has authorized the marketing of 20 ZYN nicotine pouch products. Nicotine pouches -- small synthetic fiber pouches containing nicotine -- are designed to be placed between a person's gum and lip.
FDA OKs sales of Zyn nicotine pouches, citing health benefits for adult smokers
FDA officials say that Zyn contains fewer harmful ingredients than cigarettes and other types of chewing tobacco, which are linked with cancer and other diseases.
FDA will allow Zyn nicotine pouches to stay on the market
Zyn products will be allowed to stay on the market after federal health officials said Thursday that the popular nicotine pouches can help adult smokers cut back or switch completely.
FDA approves sales and marketing for Zyn nicotine pouches
Marketing for the popular nicotine pouch product, Zyn, has been approved by the U.S. Food and Drug Administration to help smokers quit cigarettes and other tobacco products.
FDA Approves ZYN Nicotine Pouches As Safer Alternative For Adult Tobacco Users
ZYN pouches contain no tobacco, only nicotine, offering a potentially less harmful option for tobacco users, with lower levels of cancer-causing constituents than traditional tobacco products.
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
BioSpace10d
FDA Proposes Setting Bar for Weight-Loss Therapies as Obesity Space Heats Up
In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
HealthDay on MSN10d
Some GLP-1s Achieve More Weight Loss Than Others: Study
Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...
6 Best Weight Loss Treatments: Ranking Top Weight Loss Solutions of 2025
Hims has become a leader in the weight loss treatment industry by offering access to men’s health solutions that are both ...
WDRB2d
Louisville pharmacy dispensing compounded weight loss drugs in effort to address shortage
Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...
STAT1d
Online marketing for compounded GLP-1 drugs overstates benefits and underplays risks
A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...
Hosted on MSN5d
Most Health Insurance Companies Cover This Weight Loss Secret
Even though some GLP-1 medications like Wegovy and Zepbound are FDA-approved for weight loss, getting insurance ...